Papantoniou Konstantinos, Aggeletopoulou Ioanna, Michailides Christos, Pastras Ploutarchos, Triantos Christos
Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece.
Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece.
Biology (Basel). 2024 Nov 18;13(11):945. doi: 10.3390/biology13110945.
Acute pancreatitis (AP) remains a serious clinical condition, with current treatment options being largely supportive. The discovery of inflammasomes, particularly the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, has significantly advanced our knowledge regarding many inflammatory diseases' pathogenesis, including AP. The NLRP3 inflammasome is central in mediating the inflammatory process in AP through its diverse activation mechanisms and its involvement in multiple signal transduction pathways. This has made NLRP3 an appealing target for novel therapeutic strategies aimed at modulating inflammation in AP. Despite the growing interest in NLRP3 as a therapeutic target, there remains a notable gap in clinical research, with few clinical trials exploring the efficacy of NLRP3 inhibitors in AP. Results of several preclinical studies and animal models are promising and suggest that the use of NLRP3 inhibitors could result in reduced inflammation and improved patient outcomes in AP. Further research is urgently needed to assess their potential benefits, safety, and applicability in human patients and address the underlying inflammatory processes driving AP.
急性胰腺炎（AP）仍然是一种严重的临床病症，目前的治疗选择主要是支持性的。炎性小体的发现，特别是含NOD样受体家族pyrin结构域3（NLRP3）炎性小体，极大地推进了我们对包括AP在内的许多炎症性疾病发病机制的认识。NLRP3炎性小体通过其多样的激活机制及其参与多种信号转导途径，在介导AP的炎症过程中起核心作用。这使得NLRP3成为旨在调节AP炎症的新型治疗策略的一个有吸引力的靶点。尽管对NLRP3作为治疗靶点的兴趣日益浓厚，但临床研究仍存在显著差距，很少有临床试验探索NLRP3抑制剂在AP中的疗效。几项临床前研究和动物模型的结果很有前景，表明使用NLRP3抑制剂可能会减轻AP的炎症并改善患者预后。迫切需要进一步研究以评估其在人类患者中的潜在益处、安全性和适用性，并解决驱动AP的潜在炎症过程。
